m+Medelevator.RU
← Поиск публикаций
ACS omega · 2025

A Self-Assembling Cross-Protective Antigen Against Multiple Gram-Positive Nosocomial Pathogens.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Kramarska Eliza, Romero-Saavedra Felipe, Squeglia Flavia, Manna Sara La, Sadones Oceane, Marasco Daniela, Berisio Rita, Huebner Johannes

Аннотация

ESKAPE pathogens are responsible for complicated nosocomial infections worldwide and are usually resistant to commonly used antibiotics in clinical settings. Among these bacteria, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus are the two most important Gram-positive pathogens for which alternative treatments and preventions are urgently needed. We previously designed a multipresenting antigen, embedding the main epitope displayed by the AdcA protein of E. faecium, that conferred protection against different Gram-positive pathogens both in passive and active immunization models. Here, we developed a new presentation strategy for this epitope, the EH-motif, based on a self-assembling peptide. Self-assembling peptides have been promising in the fields of material sciences, nanoscience, and medicine and have also potential in vaccine development, as they allow multiple presentations of the epitope and provide an ideal size for production and application. We show that this multipresenting peptide, here Q11-EH, forms stable fibers of nanometric size. We also demonstrate that antibodies raised against Q11-EH mediate the opsonic killing of a wide spectrum of Gram-positive pathogens, including E. faecium, S. aureus, and E. faecalis. Our data indicate that multiple presentation strategies are a potent tool for vaccine antigen improvement and point to Q11-EH as a promising antigen for the development of novel cross-protective vaccines.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты